Crinetics Pharmaceuticals Inc(CRNX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -5.05 | Insider Own | 4.01% | Shs Outstand | 105.8M | Perf Week | - |
| Market Cap | 9.01B | Forward P/E | - | EPS next Y | 11.91% | Insider Trans | -3.24% | Shs Float | 101.8M | Perf Month | 0.7% |
| Enterprise Value | 7.85B | PEG | - | EPS next Q | -1.19 | Inst Own | 100.27% | Short Float | 6.73% | Perf Quarter | 147.52% |
| Income | -0.50B | P/S | 213.7 | EPS this Y | 4.98% | Inst Trans | - | Short Ratio | 1.69 | Perf Half Y | 129.72% |
| Sales | 0.04B | P/B | 7.54 | EPS next 5Y | 16.23% | ROA | -38.42% | Short Interest | 6.85M | Perf YTD | 82.49% |
| Book/sh | 11.27 | P/C | 7.47 | EPS past 3/5Y | -16.2% -15.33% | ROE | -42.45% | 52W High | -0.07% ($85.01) | Perf Year | 174.12% |
| Cash/sh | 11.37 | P/FCF | - | Sales past 3/5Y | 17.56% - | ROIC | -40.7% | 52W Low | 174.03% ($31.00) | Perf 3Y | 390.47% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -22.68% | Gross Margin | 86.55% | Volatility(W/M) | 0.08% 0.2% | Perf 5Y | 260.42% |
| Dividend TTM | - | EV/Sales | 186.22 | Sales Y/Y TTM | 2928.45% | Oper. Margin | -1302.52% | ATR (14) | 0.41 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 15.53 | EPS Q/Q | 7.14% | Profit Margin | -1189.88% | RSI (14) | 89.79 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 15.57 | Sales Q/Q | 2336.28% | SMA20 | 0.5% ($84.53) | Beta | 0.02 | Target Price | $85 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/3 | SMA50 | 13.52% ($74.83) | Rel Volume | 0 | Prev Close | $84.95 |
| Employees | 594 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 3.28% 69.24% | SMA200 | 68.41% ($50.44) | Avg Volume(3M) | 4.04M | Price | $84.95 |
| IPO | 2018/7/18 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
A biopharmaceutical company developing therapeutics for endocrine disorders. The company is developing oral treatments targeting endocrine diseases such as acromegaly and is pursuing commercialization based on late-stage clinical results. It is a biopharmaceutical firm specialized in therapeutics for endocrine disorders.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
CRNX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +5.0% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $21,370. Peers typically go for $1,648.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +260.4%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 100.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #32 of 595 in the industry
Based on market cap of $9B.
IBRX#29 ImmunityBio Inc $9B PER - 
SYRE#30 Spyre Therapeutics Inc $9B PER - 
PTGX#31 Protagonist Therapeutics Inc $9B PER 136.1 CRNX#32 Crinetics Pharmaceuticals Inc $9B PER - 
TGTX#32 TG Therapeutics Inc $9B PER 20.6 
FAQ
What kind of company is CRNX?
CRNX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CRNX?
The market cap of CRNX is approximately $9.0B, ranking 1,010 within its sector.
What is the 52-week high and low for CRNX?
CRNX has recorded a 52-week high of $85.01 and a low of $31.00.
